EARNINGS

DX Earnings Report: Lab Market Consolidates but Survivors Stay Strong

PAMA and private payor rate cuts and increased market competitiveness are fueling consolidation and driving smaller, independent labs (other than specialty labs) into near extinction. But the big, … [Read more...]

INDUSTRY BUZZ

Industry Buzz: Qiagen and the Terrible, Horrible, No Good, Very Bad Day

Qiagen has been leaking oil for a while now. But after months of disappointing sales and dashed expectations, things came to a dramatic head over the less than 24 hour period between Oct. 7 and 8, … [Read more...]

REVENUES

DX Earnings Report: Markets Soften, Payors Harden but Growth Continues

Lab business is getting tougher. While PAMA cuts are hurting Medicare revenues, pressure from private payors may be even more intense both at the pricing front end and claims denial back end. Economic … [Read more...]

REVENUES

DX Earnings Report: Lab Companies Continue to Grow but at a Slower Rate

The diagnostics industry got off to a so-so start with PAMA reimbursement cuts, a weak flu season relative to 2018 and currency translation slowing the pace of year-over-year revenue … [Read more...]

EARNINGS REPORTS

DX Earnings Report: Lab Companies Finish 2018 Strong but Growth Slows for Established Firms

The diagnostics industry capped a robust 2018 with most companies posting strong fourth quarter results. Of course, every silver lining has a cloud. While widespread, gains were smaller than in 2017, … [Read more...]

INDUSTRY BUZZ

Earnings Report: Top Payers Announce Q3 Earnings

The country's five largest commercial payers posted strong results for the third quarter of fiscal year 2018: COMPANY QUARTERLY REVENUES PERFORMANCE Total Q3* 2018 YOY Wall … [Read more...]

REVENUES

DX Earnings Report: Q2 Lab Earnings Stay Strong but Not Quite at Q1 Levels

Q2 is shaping up to be another strong quarter—albeit not as stellar as Q1. Salient trends: Big labs continue posting impressive organic growth even as they enjoy the surge of new revenues from … [Read more...]

PAMA

PAMA Unlocks Golden Age for Innovative Diagnostics

By Chance Scott  bio The publication of the 2018 Clinical Laboratory Fee Schedule (CLFS) in January saw a long and heated debate within the lab community come to fruition. When Congress … [Read more...]

REVENUES

DX Earnings Report: PAMA Cuts Make Little Dent on Q1 Lab Earnings

One quarter into its existence, the new PAMA Medicare Part B fee schedule seems to be having only a marginal impact on at least publicly traded labs. In fact, the recently published Q1 earnings … [Read more...]

REVENUES

DX Earnings Report: PAMA Cuts Make Little Dent on Q1 Lab Earnings

One quarter into its existence, the new PAMA Medicare Part B fee schedule seems to be having only a marginal impact on at least publicly traded labs. In fact, the recently published Q1 earnings … [Read more...]


(-00000g2)